Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials.

  • 2024-11-12
  • Current diabetes reports 25(1)
    • Feng Chen
    • Disheng Zhou
    • Alice Pik-Shan Kong
    • Nga Ting Yim
    • Siyu Dai
    • Yu Nan Chen
    • Lai Ling Hui

Study Design

Type
Meta-Analysis
Sample size
n = 342
Population
342 middle-age/older adults (49% females, mainly non-diabetic)
Methods
random-effects meta-analyses of eight RCTs on NMN (dosage ranged 250–2000 mg/d for a duration of 14 days to 12 weeks)

Purpose of review

Supplementation of nicotinamide mononucleotides (NMN) has been claimed to improve metabolic function. We reviewed human randomised controlled trials (RCTs) of NMN to evaluate its effect on markers of glucose and lipid metabolism.

Recent findings

Eight RCTs on NMN (dosage ranged 250-2000 mg/d for a duration of 14 days to 12 weeks) involving a total of 342 middle-age/older adults (49% females, mainly non-diabetic) reporting at least one outcome on glucose control or lipid profile published in 2021-2023 were reviewed. The random-effects meta-analyses indicated no significant benefit of NMN on fasting glucose, fasting insulin, glycated hemoglobin, homeostatic model assessment for insulin resistance and lipid profile. Based on the small number of RCTs involving mainly relatively healthy adults, short-term supplementation of NMN of 250-2000 mg/d did not show significantly positive impacts on glucose control and lipid profile.

Research Insights

    Back to top